Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report)'s stock had its "sell (d-)" rating reiterated by Weiss Ratings in a research note issued on Wednesday,Weiss Ratings reports.
Other equities research analysts have also issued reports about the stock. UBS Group lifted their price target on shares of Teva Pharmaceutical Industries from $23.00 to $26.00 and gave the company a "buy" rating in a report on Wednesday, September 24th. JPMorgan Chase & Co. boosted their target price on shares of Teva Pharmaceutical Industries from $23.00 to $26.00 and gave the stock an "overweight" rating in a research note on Friday, October 3rd. Finally, Wall Street Zen upgraded Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating in a research note on Saturday, July 26th. Two investment analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus target price of $25.57.
Check Out Our Latest Stock Analysis on TEVA
Teva Pharmaceutical Industries Price Performance
NYSE TEVA traded up $0.15 on Wednesday, hitting $20.22. 13,054,822 shares of the company's stock were exchanged, compared to its average volume of 11,866,204. The stock has a 50-day moving average of $18.33 and a 200-day moving average of $16.89. The stock has a market cap of $23.19 billion, a price-to-earnings ratio of -126.38, a P/E/G ratio of 1.16 and a beta of 0.71. Teva Pharmaceutical Industries has a 52 week low of $12.47 and a 52 week high of $22.80. The company has a current ratio of 1.06, a quick ratio of 0.77 and a debt-to-equity ratio of 2.45.
Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last posted its quarterly earnings results on Wednesday, July 30th. The company reported $0.66 EPS for the quarter, topping analysts' consensus estimates of $0.64 by $0.02. The company had revenue of $4.18 billion during the quarter, compared to analysts' expectations of $4.34 billion. Teva Pharmaceutical Industries had a positive return on equity of 46.10% and a negative net margin of 0.95%.Teva Pharmaceutical Industries's revenue was up .3% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.61 EPS. Teva Pharmaceutical Industries has set its FY 2025 guidance at 2.500-2.600 EPS. Analysts expect that Teva Pharmaceutical Industries will post 2.5 earnings per share for the current year.
Insider Buying and Selling at Teva Pharmaceutical Industries
In related news, insider Placid Jover sold 6,053 shares of the firm's stock in a transaction on Friday, August 1st. The stock was sold at an average price of $15.16, for a total transaction of $91,763.48. Following the completion of the transaction, the insider directly owned 6,774 shares of the company's stock, valued at $102,693.84. This trade represents a 47.19% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Eric A. Hughes sold 52,742 shares of the company's stock in a transaction dated Friday, August 1st. The shares were sold at an average price of $15.16, for a total value of $799,568.72. The disclosure for this sale can be found here. 0.55% of the stock is owned by company insiders.
Institutional Inflows and Outflows
Hedge funds have recently added to or reduced their stakes in the company. Ion Asset Management Ltd. lifted its position in shares of Teva Pharmaceutical Industries by 6.5% in the 1st quarter. Ion Asset Management Ltd. now owns 39,033,500 shares of the company's stock worth $599,945,000 after purchasing an additional 2,383,500 shares during the period. Menora Mivtachim Holdings LTD. raised its stake in Teva Pharmaceutical Industries by 31.9% during the second quarter. Menora Mivtachim Holdings LTD. now owns 38,493,294 shares of the company's stock worth $645,148,000 after buying an additional 9,303,978 shares during the last quarter. Phoenix Financial Ltd. lifted its holdings in Teva Pharmaceutical Industries by 31.7% in the second quarter. Phoenix Financial Ltd. now owns 37,761,444 shares of the company's stock valued at $632,882,000 after buying an additional 9,094,372 shares during the period. Harel Insurance Investments & Financial Services Ltd. boosted its position in Teva Pharmaceutical Industries by 51.4% during the second quarter. Harel Insurance Investments & Financial Services Ltd. now owns 33,390,327 shares of the company's stock valued at $559,622,000 after acquiring an additional 11,334,780 shares during the last quarter. Finally, Migdal Insurance & Financial Holdings Ltd. boosted its position in Teva Pharmaceutical Industries by 8.9% during the second quarter. Migdal Insurance & Financial Holdings Ltd. now owns 28,685,422 shares of the company's stock valued at $480,768,000 after acquiring an additional 2,350,000 shares during the last quarter. Institutional investors own 54.05% of the company's stock.
About Teva Pharmaceutical Industries
(
Get Free Report)
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Teva Pharmaceutical Industries, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Teva Pharmaceutical Industries wasn't on the list.
While Teva Pharmaceutical Industries currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
